Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.75 |
| ▸ | DRD4 | P21917 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.64 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5206645 | 0.95 | POLB (0.68) | POLBDRD4ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL3151686 | 0.94 | POLB (0.71) | POLBDRD4ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL8125916 | 0.91 | MEN1 (0.68) | POLBALDH1A1MAPTL3MBTL1MCHR1 | |
| SCHEMBL5626457 | 0.89 | ALDH1A1 (0.74) | ALDH1A1MAPTL3MBTL1NPBWR1MCHR1 | |
| SCHEMBL25368316 | 0.87 | POLB (0.73) | POLBALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL15347670 | 0.87 | POLB (0.73) | POLBDRD4ALDH1A1MAPTNPBWR1 | |
| SCHEMBL4506302 | 0.87 | POLB (0.65) | POLBDRD4ALDH1A1MAPTNPBWR1 | |
| SCHEMBL11549718 | 0.86 | POLB (0.71) | POLBALDH1A1MAPTNPBWR1MCHR1 | |
| SCHEMBL11556051 | 0.86 | POLB (0.71) | POLBALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL11550138 | 0.86 | POLB (0.75) | POLBALDH1A1MAPTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452168-B2 | Pyrrole antifungal agents | F2G LTD (GB) | 2016-09-27 | — | — | US | disclosed |
| CN-101336237-B | As the pyrimidinyl aryl urea derivatives of FGF inhibitor | NOVARTIS AG (CH) | 2015-09-30 | — | — | CN | disclosed |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-08-27 | — | — | US | disclosed |
| EP-1976847-B1 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2015-06-17 | — | — | EP | disclosed |
| US-8993574-B2 | Pyrrole antifungal agents | F2G LTD (GB) | 2015-03-31 | — | — | US | disclosed |
| EP-2283006-B1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-02-25 | — | — | EP | disclosed |
| EP-2626361-B1 | Pyrrole antifungal agents | F2G LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| US-8759517-B2 | Pyrirnidinyl aryl urea derivatives being FGF inhibitors | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| EP-2626361-A1 | Pyrrole antifungal agents | F2G Limited (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20130030171-A1 | Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors | NOVARTIS AG (CH) | 2013-01-31 | — | — | US | disclosed |
| US-5086055-A | Treating asthma, rhinitis, atopic dermatitis, chronic hives and conjunctivitis | A. H. ROBINS COMPANY, INCORPORATED (US) | 1992-02-04 | — | — | US | disclosed |
| US-5051423-A | Derivatized alkanolamines as cardiovascular agents | SCHERING AG (DE) | 1991-09-24 | — | — | US | disclosed |
| US-4960776-A | ANTIALLERGENS | A. H. ROBINS COMPANY, INC. (US) | 1990-10-02 | — | — | US | disclosed |
| EP-0358284-A2 | Derivatized alkanolamines as cardiovascular agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-03-14 | — | — | EP | disclosed |
| US-4906634-A | Novel N-[4-(aminosubstituted)phenyl]methanesulfonamides and their use as cardiovascular agents | SCHERING A.G. (DE) | 1990-03-06 | — | — | US | disclosed |
| WO-1990000548-A2 | DERIVATIZED ALKANOLAMINES AS CARDIOVASCULAR AGENTS | SCHERING AKTIENGESELLSCHAFT BERLIN AND BERGKAMEN (DE) | 1990-01-25 | — | — | WO | disclosed |
| US-4882330-A | 1-aryloxy-4-[((4-aryl)-1-piperazinyl]-2-butanols useful as antiallergy agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-11-21 | — | — | US | disclosed |
| EP-0332570-A2 | Novel-N-(4-(Aminosubstituted)phenyl) methanesulfonamides and their use as cardiovascular agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-09-13 | — | — | EP | disclosed |
| EP-0277725-A2 | 4-Aryl-N-[2-(dialkylamino and heterocyclicamino) alkyl]-1-piperazinecarboxamides and their use as anti allergy agents | A.H. ROBINS COMPANY, INCORPORATED (US) | 1988-08-10 | — | — | EP | disclosed |
| EP-0269383-A2 | 1-Aryloxy-4-[(4-aryl)-1-piperazinyl]-2-butanols useful as antiallergy agents | A.H. ROBINS COMPANY, INCORPORATED (US) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | FOXM1, PYCR1, ARG1 | POLB 3827/4885DRD4 1570/4885ALDH1A1 219/4885 |
| US-20130030171-A1 | Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors | FGFR1, FGF1, FGF2 | POLB 3255/4885DRD4 4846/4885ALDH1A1 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.